| Sunday, October 26 | |
|---|---|
| 1:00 – 5:00 | Optional Executive Education Program: “Financial Analysis for Life Sciences Professionals” Andrew W. Lo, MIT MIT Sloan School of Management, 2nd Floor, 100 Main Street (Building E62), Cambridge, MA 02142 Space is limited to 100 participants on a first-come-first-served basis. |
| 5:00 – 6:00 | Registration and Cocktails Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142 |
| 6:00 – 8:00 | Welcome Dinner Keynote Speaker: Clifton Leaf, Fortune Introduction by Marty Tenenbaum, Cancer Commons |
| Monday, October 27 Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142 | |
|---|---|
| 8:00 – 8:30 | Continental Breakfast and Registration |
| 8:30 – 9:00 | Welcome and Conference Background and Objectives David Schmittlein, MIT Andrew W. Lo, MIT |
| 9:00 – 10:30 | Session 1: Scientific Advances and Challenges Parag Mallick*, Stanford University; Stephen Fawell, AstraZeneca; Michael Goldberg, Dana-Farber Cancer Institute; Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT; Manolis Kellis, MIT; and Phillip Sharp, MIT |
| 10:30 – 11:00 | Break |
| 11:00 – 12:30 | Session 2: Re-Engineering the Drug Discovery Process Alan Jakimo*, Sidley Austin LLP; Christopher Austin, NCATS; Gary Kelloff, NCI; Cyrus Mehta, Cytel; Robert O’Neill, FDA; Azita Sharif, Daedalus Software |
| 12:30 – 2:00 | Lunch Keynote Speakers: Judy Lewent and Cathrin Petty, J.P. Morgan Introduction by Stewart C. Myers, MIT |
| 2:00 – 3:30 | Session 3: New and Emerging Business Models Greg Simon*, Poliwogg; Duncan Darrow, New Fund Institute; Ilan Ganot, Solid Ventures; Edward Jung, Intellectual Ventures; Tom Rutledge, Magnetar Capital; Jake Xia, Harvard Management Company |
| 3:30 – 4:00 | Break |
| 4:00 – 5:30 | Session 4: Funding, Structuring, and Investor Perspectives, Part 1 Jose Maria Fernandez*, Spanish Treasury, Ministry for the Economy and Competition; Doug Dachille, First Principles Capital Management; Sandra M. Forman, Proskauer; Alison Li, CalPERS; Rosemarie Loffredo, Leukemia & Lymphoma Society; Anna Makki, Credit Suisse |
| 5:30– 6:00 | Day 1 Conference Wrap-Up |
| 6:00 | Dinner Keynote Speaker: Pablo Legorreta, Royalty Pharma Introduction by S. P. Kothari, MIT |
| Tuesday, October 28 Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142Memorial Drive (Building E52), Cambridge, MA 02142 | |
|---|---|
| 8:00 – 8:30 | Continental Breakfast |
| 8:30 – 10:00 | Session 5: Innovations from Big Pharma Monique Mansoura*, Novartis; Ann Dewitt, Sanofi-Genzyme Bioventures; Jose-Carlos Gutierrez-Ramos, Pfizer; Jeb Keiper, Nimbus Discovery; Juan Carlos Lopez, Roche; Darren Snellgrove, Johnson & Johnson Innovation |
| 10:00 – 10:30 | Break |
| 10:30 – 12:00 | Session 6: Economics of Biomedical Innovation Andrew W. Lo*, MIT; Rena Conti, University of Chicago; Joseph Dimasi, Tufts Center for the Study of Drug Development; Bruce Lehmann, University of California, San Diego; Tom Philipson, University of Chicago; Vikas Sukhatme, Beth Israel Deaconess |
| 12:00 – 1:30 | Lunch Keynote Speaker: Eric Lander, The Broad Institute Introduction by Larry Norton, Memorial Sloan Kettering Cancer Center |
| 1:30 – 3:00 | Session 7: Funding, Structuring, and Investor Perspectives, Part 2 Roger Stein*; Francois Boissel, Novadiscovery; John Frishkopf, NewStar Financial; Michael Millette, Goldman Sachs; Issi Rozen, The Broad Institute; David Sabow, Silicon Valley Bank |
| 3:00 – 3:30 | Break |
| 3:30 – 5:00 | Session 8: The Role of Government, Patient Advocacy, and Philanthropy Doug Criscitello*, Grant Thornton; Karen Shaw Petrou, Federal Financial Analytics; Syril Pettit, ILSI Health and Environmental Sciences Institute; Leslie Platt, Innovation Financing Roundtable; Kenneth Schaner, Schaner & Lubitz; Christiana Stamoulis, Hologic, Inc. |
| 5:00 – 5:30 | Day 2 Conference Wrap-Up |
* Session Moderator